Skip to main content

Table 1 Comprehensive inclusion and exclusion criteria

From: Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial

Inclusion Exclusion
Adults (aged ≥ 30 years)
T2D with HbA1c ≥ 6.0% and < 9.0%
Pre-existing CKD with
(i) 30 mL/min/1.73 m2 ≤ eGFR < 60 mL/min/1.73 m2 and/or
(ii) albuminuria ≥ 30 mg/g Cr
Patients with RHI < 2.10 at pre-testing RH-PAT within 3 mo prior to randomization
Patients who received an explanation of the study and provided written informed consent
Type 1 diabetes
History of clinically apparent atherosclerotic CVDs such as CAD, stroke, PAD, and
symptomatic carotid artery stenosis
History of arterial fibrillation
History of severe ketosis, diabetic coma, or precoma attack ≤ 6 mo prior to informed consent
Severe renal dysfunction (eGFR < 30 mL/min/1.73 m2 or undergoing dialysis)
Patients received SGLT2is within 3 mo before informed consent
Patients who changed the glucose-lowering medications within 3 mo before informed consent
Hypersensitivity to ipragliflozin or other SGLT2is
Symptomatic hypotension, or systolic blood pressure < 90 mm Hg
Patients with severe infection or trauma at screening
Patients in perioperative period around screening
Polysystic kidney disease, lupus nephritis, or ANCA-related vasculitis
Pregnant or suspected pregnancy
Considered inappropriate for the study by investigators due to other reasons such as malignancy
  1. ANCA antineutrophil cytoplasmic antibody; CAD coronary artery disease; CVDs cardiovascular diseases; CKD chronic kidney disease; eGFR estimated glomerular filtration rate; PAD peripheral artery disease; RHI reactive hyperemia index; RH-PAT reactive hyperemia peripheral arterial tonometry; SGLT2is sodium glucose cotransporter 2 inhibitors; TIA transient ischemic attack; T2D type 2 diabetes